

Biota Holdings Limited

ACN 006 479 081

10/585 Blackburn Road
Notting Hill VIC 3168
Australia**T** +61 3 9915 3700**F** +61 3 9915 3702**E** info@biota.com.au**W** www.biota.com.au*For Immediate Release*

Melbourne, Australia — 23 October 2012

Nabi shareholder meeting results

Biota Holdings Limited (ASX:BTA, Biota) announces that Nabi Biopharmaceuticals Inc. (Nabi) has advised that its shareholders have approved proposals related to the business combination transaction with Biota, at a shareholders meeting held at 4.30pm on Monday 22 October 2012 at Bethesda, Maryland, USA.

As set out in the Explanatory Memorandum dated 6 August 2012, Nabi shareholders were to vote on a number of proposals including the following:

- To increase the authorised shares in Nabi to 200,000,000;
- To approve the issuance of shares of Nabi to Biota shareholders as contemplated by the Merger Implementation Agreement;
- To approve, at Nabi directors' sole discretion, a share consolidation in the range of four-to-one to eight-to-one; and
- To approve the change of name from Nabi Biopharmaceuticals to Biota Pharmaceuticals Inc.

Each of these proposals were approved by the requisite majority votes.

Biota shareholders meet at 2.00pm on Tuesday 23 October 2012 in Melbourne, to approve the Revised Scheme of Arrangement in relation to the transaction. Shareholders unable to attend the meeting will be provided with further advice immediately following its conclusion.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has a well advanced program for human rhinovirus (HRV) infection with a completed Phase IIb study in asthmatic subjects.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product Inavir[®], is marketed in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Relenza[™] is a registered trademark of the GlaxoSmithKline group of companies.
Inavir[®] is registered to Daiichi Sankyo.

Further information**Investor/Analyst Enquiries****Biota Holdings Limited**

Peter Cook

T: +61 3 9915 3720

Damian Lismore

T: +61 3 9915 3721

Shareholder Enquiries

Biota Shareholder Information Line

T: 1300 306 230 (within Australia)

T: +61 2 8280 7169 (International)

Between 8.30am and 7.30pm

(Melbourne time)

Media Enquiries

Nerida Mossop, Hinton & Associates

T: +61 3 9600 1979 / M: +61 437 361 433

Felicity Williams, Hinton & Associates

T: +61 3 9600 1979 / M: +61 416 770 012

US Enquiries

Hershel Berry, Blueprint Life Science Group

M: +1 415 505 3749